Welcome to our dedicated page for Privia Health Group news (Ticker: PRVA), a resource for investors and traders seeking the latest updates and insights on Privia Health Group stock.
Privia Health Group operates as a U.S. physician enablement company focused on primary-care centric medical groups, risk-bearing entities and the Privia Platform of technology and service solutions. The company works with medical groups, health plans and health systems to build provider networks and support value-based care.
Company updates commonly cover quarterly and annual operating results, guidance, practice collections, care margin, platform contribution, adjusted EBITDA and provider growth. Recurring developments also include performance in value-based risk arrangements, expansion into new or existing states, material agreements, capital-structure disclosures and governance matters.
Privia Health (Nasdaq: PRVA) appointed Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026, and named her to the Board’s Compliance Committee.
According to Privia Health, Dr. Ernest brings more than 20 years of healthcare executive experience, including senior leadership roles at Health Care Service Corporation (HCSC). She currently serves as President, HCSC Markets, and previously was Executive Vice President and Chief Operating Officer, overseeing strategy, clinical operations, performance, and growth across market segments.
A board-certified family physician, she earned her medical degree from The Ohio State University College of Medicine and a bachelor’s degree from the University of Michigan. Dr. Ernest also holds board positions at World Business Chicago and the Museum of Science and Industry and has been recognized by the American Heart Association for her work addressing health issues.
Privia Health (Nasdaq: PRVA) reported second-quarter 2026 revenue of $632.6 million, up 21.4% year over year, with gross profit of $128.9 million and operating income of $11.8 million. Net income attributable to Privia rose to $9.0 million, a 236.7% increase, or $0.07 per share, while non-GAAP adjusted net income reached $25.3 million. Adjusted EBITDA grew 29.1% to $37.4 million.
Key operating metrics also expanded, with 5,644 implemented providers (+10.1%) and 1.647 million value-based attributed lives (+19.2%). For the first half of 2026, revenue rose 23.5% to $1.24 billion and adjusted EBITDA increased 32.6% to $74.1 million. Privia raised full-year 2026 guidance across all major metrics, now targeting GAAP revenue at the high end of $2.35–$2.45 billion, and Adjusted EBITDA in the $145–$155 million range at the mid to high end, and expects about 70–80% of Adjusted EBITDA to convert to free cash flow.
Privia Health (Nasdaq: PRVA) will release its second-quarter and six-month 2026 financial results for the period ended June 30, 2026, before market open on Thursday, August 6, 2026.
Management will host a conference call and live webcast at 8:00 am ET the same day to review results and discuss the outlook.
Privia Health (Nasdaq: PRVA) signed a definitive agreement to enter New Jersey, its 25th state, by partnering with Neurology Group of Bergen County, a 25-clinician adult and pediatric neurology practice.
NGBC will be the anchor for Privia Medical Group—New Jersey and is expected to be implemented on the Privia Platform by year-end 2026, offering community clinicians support across reimbursement models.
Privia Health (Nasdaq: PRVA) reported 1Q 2026 results for the period ended March 31, 2026, with revenue of $603.8M (up 25.8% YoY) and adjusted EBITDA of $36.7M (up 36.3% YoY). Practice collections were $914.8M (+14.6%) and attributed lives rose to 1,606,000.
The company reiterated full‑year 2026 guidance and raised its attributed lives range to 1.600M–1.625M, while GAAP net income was $3.1M and included $21.9M of stock‑based compensation.
Privia Health (Nasdaq: PRVA) will report results for the quarter ended March 31, 2026 before market open on Thursday, May 7, 2026. The release is expected by 7:00 AM ET, with a management conference call at 8:00 AM ET the same day.
Investors can access a live webcast or on-demand replay at ir.priviahealth.com. To join the live call, dial 888-596-4144 (domestic) or 646-968-2525 (international) and use Conference ID 5704885.
Privia Health (Nasdaq: PRVA) earned the 2026 HFMA MAP Award for High Performance in Revenue Cycle, marking recognition in nine of the last ten years. The award reflects sustained excellence across MAP Keys® metrics such as net collection rate, AR performance, denial prevention, and cost to collect.
Privia’s multi-year transformation—analytics, AI automation, provider engagement, and scalable operating models—drove strong MAP benchmark results and the national award presented March 18 at the HFMA Revenue Cycle Conference.
Privia Health (NASDAQ:PRVA), Amalgam Rx, and Exact Sciences (NASDAQ:EXAS) report a Privia-led colorectal cancer screening program that reached an 84% screening rate in 2024, above the 80% national goal. The EHR-integrated, automated outreach program engaged >42,000 patients (scaled to >100,000), processed ~23,000 orders within 48 hours, and found a 10% positivity rate identifying >550 patients needing follow-up.
The program used Cologuard as a noninvasive first-line option and embedded ordering, results, and follow-up into athenaClinicals to support value-based care and eCQM readiness.
Privia Health (Nasdaq: PRVA) reported full-year 2025 results with all operating and financial metrics at or above the high end of guidance. Total revenue was $2,122.8M (+22.3%), Adjusted EBITDA $125.5M (+38.8%), and net income $22.9M (+59.3%).
Year-end cash was $479.7M with no debt; 2025 operating cash flow was $163.4M (+49.5%). 2026 guidance targets ~20% Adjusted EBITDA growth at midpoint and expects ~80% conversion of Adjusted EBITDA to free cash flow.
Privia Health (Nasdaq: PRVA) expects to release financial results for the fourth quarter and full year ended December 31, 2025 before market open on Thursday, February 26, 2026. The release is expected to be publicly available by 7:00 AM ET and on the company's investor relations website. Management will host a conference call and live webcast to discuss results and outlook beginning at 8:00 AM ET the same day; the webcast will be archived for on-demand replay. To join the live call, dial 888-596-4144 (or 646-968-2525 internationally) and use Conference ID 5704885.